Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
•
https://corcept.com/wp-content/uploads/COR-logo.svg00jeremiah@devisedesigns.comhttps://corcept.com/wp-content/uploads/COR-logo.svgjeremiah@devisedesigns.com2023-01-13 00:00:002023-01-13 00:00:00Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
